This study will exploratively evaluate the safety, tolerability and pharmacokinetics of DA-5223 compared with DA-5223-R in healthy adult subjects
Adult male or female, 19 years to 55 years
Male weighing 50 kg or more, female weighing 45 kg or more with a body mass index (BMI) of 18.0 kg/m2 to 30.0 kg/m2
The subjects signed and dated informed consent form after hearing a detailed explanation of the study, fully understanding and determined voluntarily to participate
The subjects with acute illness
The subjects with a history of gastrointestinal disease or surgery that may affect the absorption of Investigational Product
The subjects hypersensitive to any of the Investigational Product components or other drug components
The subjects who have continuously consumed excessive smoking or alcohol within 1 months of screening, or who cannot stop smoking, caffeine, or alcohol intake during hospitalization
Crossover
DA-5223-R
Drugonce a day
DA-5223-F
Drugonce a day
DA-5223-M
Drugonce a day
AUClast
Area under the plasma concentration-time curve from time zero to time the last quantifiable time
Cmax
Peak Plasma Concentration
Click on the lead sponsor to view all of their trials.
